ONTXONTEX GROUP


$ 0.63 $ -0.01 (-0.87 %)    

Friday, 03-May-2024 14:39:04 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 0.636
$ 0.63
$ 0.00 x 0
$ 0.66 x 100
$ 0.63 - $ 0.63
$ 0.55 - $ 1.45
110,618
na
nm
$ 1.20
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 onconova-therapeutics-narazaciclib-ash-poster-highlights-activity-in-treatment-resistant-mantle-cell-lymphoma

Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standa...

 why-icosavax-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax ...

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...

 why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

 onconova-therapeutics-preclinical-narazaciclib-data-at-sabcs-highlights-differentiated-anti-tumor-activity-v-other-cdk46is

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with...

 onconova-therapeutics-q3-2023-eps-023-beats-029-estimate-sales-5700k-miss-7000k-estimate

Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of...

 onconova-therapeutics-q3-eps-023-beats-029-estimate-sales-5700k-miss-7000k-estimate

Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of...

 earnings-scheduled-for-november-14-2023

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue o...

 hc-wainwright--co-reiterates-buy-on-onconova-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Onconova Therapeutics (NASDAQ:ONTX) with a Buy and maintains $11...

 onconova-therapeutics-announces-rigosertib-data-presented-at-eadv-as-late-breaker

Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical comp...

 hc-wainwright--co-reiterates-buy-on-onconova-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Onconova Therapeutics (NASDAQ:ONTX) with a Buy and maintains $11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION